Astellas

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatmentmore

Tokyo, JapanPharmaceuticals & BiotechEnterprise

Partnerships

Procurement Foundry

Operator of an online community of strategic sourcing professionals intended to offer a place for them to converse, share and grow from collective knowledge. The company's community offers a place where knowledge, ideas, questions, and information are shared through chat channels, webinars, AMA (ask me anything) sessions, real-time surveys, document libraries, and presentation theaters, enabling members to gather, grow and share knowledge with their peers.

Fairhaven, United States of AmericaMedia & Entertainment

Partnerships

Employees

14,754

Featured companies:

Similar to Astellas

View all companies

Kyowa Kirin

Delivering Life-changing value as a Global Specialty Pharmaceutical company.

Chiyoda-ku, Tokyo, Japan

Daiichi Sankyo

Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lungmore

Tokyo, JapanPharmaceuticals & Biotech